Fumarate ester pharmaceutical compositions
View Patent ↗Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.
1. A method for treating or reducing symptoms of multiple sclerosis or psoriasis comprising orally administering to a subject in need thereof an immediate release pharmaceutical composition comprising one or more fumarate esters suspended in a single phase liquid matrix comprising a lipid liquid or lipophilic liquid vehicle at a weight ratio of fumarate ester to matrix from about 1:1 to about 1:9.
2. The method of claim 1 , wherein the composition comprises about 60 mg to about 240 mg of fumarate ester.
3. The method of claim 1 , wherein the fumarate ester comprises dimethyl fumarate, monomethyl fumarate, or a combination thereof.
4. The method of claim 1 , wherein the fumarate ester comprises dimethyl fumarate.
5. The method of claim 1 , wherein the fumarate ester comprises monomethyl fumarate.
6. The method of claim 1 , wherein the lipid liquid or lipophilic liquid vehicle comprises a vegetable oil, fatty acid, fatty acid ester, or a combination thereof.
7. The method of claim 1 , wherein the lipid liquid or lipophilic liquid vehicle consists of soybean oil.
8. The method of claim 1 , wherein the lipid liquid or lipophilic liquid vehicle comprises a mixture of mono- and di-glycerides, polyvinylpyrrolidone, and polyoxyl 40 hydrogenated castor oil.
9. The method of claim 1 , wherein the matrix further comprises lactic acid.
10. The method of claim 1 , wherein the subject experiences one or more of flushing, abdominal pain, diarrhea, or nausea at a rate of less than about 20%.
11. The method of claim 1 , wherein the composition is encapsulated in a soft capsule or an enteric soft capsule.
12. The method of claim 11 , wherein the soft capsule comprises an enteric soft capsule that provides delayed release of the fumarate ester.
13. The method of claim 1 , wherein two dosage forms of the composition are simultaneously administered to the subject twice per day.
14. A method for treating or reducing symptoms of multiple sclerosis or psoriasis comprising orally administering to a subject in need thereof an immediate release pharmaceutical composition comprising:
about 10% to about 50% of one or more fumarate esters comprising dimethyl fumarate, monomethyl fumarate, or a combination thereof; and
about 50% to about 90% of a single phase lipid liquid or lipophilic liquid vehicle.
15. The method of claim 14 , wherein the composition comprises of about 60 mg to about 240 mg of fumarate ester.
16. The method of claim 14 , where in the single phase lipid liquid or lipophilic liquid vehicle comprises a mixture of mono- and di-glycerides, polyvinylpyrrolidone, polyoxyl 40 hydrogenated castor oil, and lactic acid.
17. The method of claim 14 , wherein the single phase lipid liquid or lipophilic liquid vehicle consists of soybean oil.
18. The method of claim 14 , wherein the fumarate ester comprises dimethyl fumarate.
19. The method of claim 14 , wherein the fumarate ester comprises monomethyl fumarate.
20. The method of claim 14 , wherein the subject experiences one or more of flushing, abdominal pain, diarrhea, or nausea at a rate of less than about 20%.
21. The method of claim 14 , wherein the pharmaceutical composition is encapsulated in a soft capsule or an enteric soft capsule.
22. The method of claim 14 , wherein two dosage forms of the composition are simultaneously administered to the subject twice per day.
23. A method for treating or reducing symptoms of multiple sclerosis or psoriasis comprising orally administering to a subject in need thereof a dosage from comprising a soft capsule encapsulating an immediate release composition comprising
about 10% to about 50% of dimethyl fumarate, monomethyl fumarate, or a combination thereof; and
about 50% to about 90% of a single phase liquid vehicle comprising a lipid liquid or lipophilic liquid.
24. The method of claim 23 , wherein the single phase liquid vehicle comprises a mixture of mono- and di-glycerides, polyvinylpyrrolidone, and polyoxyl 40 hydrogenated castor oil.
25. The method of claim 23 , wherein the dosage from comprises about 60 mg to about 120 mg of fumarate ester.
26. The method of claim 25 , wherein two dosage forms are simultaneously administered to the subject twice per day.
27. The method of claim 23 , wherein the dosage form comprises about 120 mg to about 220 mg of fumarate ester.
28. The method of claim 27 , wherein one dosage form is administered to the subject twice per day.
29. The method of claim 23 , wherein the soft capsule comprises an enteric soft capsule that provides delayed release of the fumarate ester.